What they were paid
Seres Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $62,500 | $0 | $50,875 | $0 | $113,375 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Seres Therapeutics, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182036, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Seres Therapeutics pays directors a $45,000 cash retainer.
Committees
FY2025 · as the proxy prints themAudit (Chair) · Nominating/Governance
The rest of the Seres Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Claire M. Fraser, Ph.D | Independent Director | $151,688 |
| Dennis A. Ausiello, M.D | Independent Director | $131,688 |
| Eric D. Shaff | Director | $0 |
| Hans-Juergen Woerle, M.D., Ph.D | Independent Director | $132,362 |
| Kurt C. Graves | Independent Director | $88,375 |
| Richard N. Kender | Chair of the Board | $123,375 |
| Robert Rosiello | Independent Director | $147,115 |
| Stephen A. Berenson | Independent Director | $168,985 |
The full Seres Therapeutics compensation record
free company briefThis page is one director within Seres Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat